Oramed Pharmaceuticals Inc. ORMP NASDAQ

Oramed Pharmaceuticals Inc. (ORMP) reported total assets of $97.59M and total liabilities of $12.03M for fiscal year 2025, resulting in total equity of $199.74M.

The company held $51.36M in cash and short-term investments. Total debt stood at $825K, with net debt of $-45.12M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 6.98, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0, current ratio of 6.98 — balance sheet is strong
• MOAT (0/100) — Total assets $97.59M and equity $199.74M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 69/100 with 4/7 criteria passed.

IBRX

ImmunityBio, Inc.

$7.78

+2.37%

TERN

Terns Pharmaceuticals, Inc.

$52.71

+0.06%

ARDX

Ardelyx, Inc.

$6.30

-0.47%

CRVS

Corvus Pharmaceuticals, Inc.

$15.11

-0.92%

LXRX

Lexicon Pharmaceuticals, Inc.

$1.86

+6.29%

IMMX

Immix Biopharma, Inc.

$10.04

+1.93%

PALI

Palisade Bio, Inc.

$2.34

+13.59%

ZURA

Zura Bio Limited

$5.69

-0.52%